|
Variables
|
Internal validation cohort (n = 284)
|
External validation cohort (n = 2,181)
|
|---|
| |
CMTC-1 number (%)
|
CMTC-2 number (%)
|
CMTC-3 number (%)
|
Pvalue
|
CMTC-1 number (%)
|
CMTC-2 number (%)
|
CMTC-3 number (%)
|
P value
|
|---|
|
Total
|
92(32.4)
|
106(37.3)
|
86(30.3)
| |
805(36.9)
|
603(27.6)
|
773(35.4)
| |
|
Age
| | | | | | | | |
|
<50
|
24(26.1)
|
34(32.1)
|
21(24.4)
|
4.52E-01
|
156(19.4)
|
92(15.3)
|
242(31.3)
|
4.03E-13
|
|
> = 50
|
68(73.9)
|
72(67.9)
|
65(75.6)
| |
649(80.6)
|
511(84.7)
|
531(68.7)
| |
|
Size
| | | | | | | | |
|
<=2 cm
|
56(60.9)
|
47(44.3)
|
40(46.5)
|
4.71E-02
|
412(51.6)
|
221(37.1)
|
294(38.7)
|
6.01E-09
|
|
>2 cm
|
36(39.1)
|
59(55.7)
|
46(53.5)
| |
387(48.4)
|
374(62.9)
|
465(61.3)
| |
|
LN
| | | | | | | | |
|
(-)
|
59(64.1)
|
68(64.2)
|
56(65.1)
|
9.88E-01
|
499(62.1)
|
298(49.5)
|
358(46.6)
|
6.49E-10
|
|
(+)
|
33(35.9)
|
38(35.8)
|
30(34.9)
| |
305(37.9)
|
304(50.5)
|
411(53.4)
| |
|
Grade
| | | | | | | | |
|
1
|
20(21.7)
|
5(4.7)
|
2(2.3)
|
8.34E-17
|
161(21.4)
|
30(5.2)
|
16(2.2)
|
1.36E-125
|
|
2
|
59(64.1)
|
37(34.9)
|
18(20.9)
| |
454(60.3)
|
253(43.8)
|
143(19.4)
| |
|
3
|
13(14.1)
|
64(60.4)
|
66(76.7)
| |
138(18.3)
|
294(51.0)
|
580(78.5)
| |
|
ER
| | | | | | | | |
|
(-)
|
1(1.1)
|
0(0.0)
|
57(66.3)
|
2.20E-35
|
34(4.2)
|
17(2.8)
|
554(71.7)
|
4.26E-251
|
|
(+)
|
91(98.9)
|
106(100.0)
|
29(33.7)
| |
771(95.8)
|
586(97.2)
|
219(28.3)
| |
|
HER2+/TN
| | | | | | | | |
|
No
|
90(97.8)
|
89(84.0)
|
17(19.8)
|
4.63E-32
|
776(96.4)
|
542(89.9)
|
180(23.3)
|
2.58E-251
|
|
Yes
|
2(2.2)
|
17(16.0)
|
69(80.2)
| |
29(3.6)
|
61(10.1)
|
593(76.7)
| |
|
Eventa
| | | | | | | | |
|
No
|
91(98.9)
|
100(94.3)
|
75(87.2)
|
5.54E-03
|
686(85.2)
|
415(68.8)
|
494(63.9)
|
3.15E-22
|
|
Yes
|
1(1.1)
|
6(5.7)
|
11(12.8)
| |
119(14.8)
|
188(31.2)
|
279(36.1)
| |
- aFollow-up event, recurrence in internal validation cohort, and distant relapse and died from the specific disease in the external validation cohort. CMTC, ClinicoMolecular Triad Classification; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node status; TN, triple-negative.
